Health Care Select Sector SPDR Fund (XLV)…

Home

Daily Stock Opinions and Ratings

Health Care Select Sector SPDR Fund (XLV)

171.45

-1.81 (1.04%)

as of Sep 4, 2026, 8:00:00 pm Market Open.

90 watching

Investor Insights

Sep 5, 2026, 12:00 am

This summary was created by AI, based on 5 opinions in the last 12 months.

The Health Care Select Sector SPDR Fund (XLV) has recently garnered significant attention from investors as a strong alternative to technology stocks, particularly due to exciting developments in the pharmaceutical sector involving drugs designed to combat melanoma recurrence. The ETF is seen as a robust vehicle for investors looking to capitalize on a health care rotation, driven by stability and optimism in the sector. XLV has shown impressive performance, outpacing the S&P 500 by a notable margin over the past three months, with returns of 26.8% over the past year. The fund is characterized by a low management expense ratio (MER) and is considered a safe, steady investment with a beta of only 0.51. Analysts recommend the potential for further growth, indicating that the stock not only has a favorable yield but also a substantial upside potential, advocating for entry into healthcare stocks now as the long-term outlook remains positive.

Consensus

Buy

Valuation

Fair Value

Similar

JNJ

BUY

The recent inflows into healthcare are based on the new diet drugs like Ozempic. Novo Nordisk and Eli Lilly have benefitted from this trend. These diet drugs are the AI equivalent in healthcare, are blockbusters.

COMMENT

Parts of healthcare are doing very well: equipment, disposables, more surgical procedures, managed care. Does this translate into stronger earnings and growth even during an economic contraction?

BUY

She picked it to start the year, but it hasn't performed well in the first six months. Healthcare has lagged this year, but when the VIX is this low, you want to hold defence.

BUY

She hopes healthcare picks up in the second half. She feels we're in late cycle where staples and utilities are expensive, but healthcare performs the best among these. HC has underperformed in the first half, but should improve second half or 2024, because XLV holds so many good companies.

BUY

She expects a recession in 2024, and higher unemployment. She sees a lot of opportunity in healthcare.

TOP PICK

Defensive name that provides exposure to health care sector.
Very strong sector as health care demand not going away.
Excellent prospects for healthcare during summer months.

BUY

She's not a fan of ETFs, this single-brushstroke style of investing, but an ETF makes sense in health care, because the companies are very different. Some will excel while others will flame out (considering their drug pipelines).

BUY

As a 5-year hold The valuation is attractive, balance sheet is good and there's non-discretionary demand for the products. Many of the underlying stocks pay a good dividend.

BUY

Is bullish biotech Biotchechs like Insight are up 13%, Moderna 25% and Regeneron 6% so hitting their lows. The whole XLV is up 8.5% off its June 17 low. 91 stocks in the S&P are above their 200-day moving average, and 18 of these are healthcare. This is the best sector to be overweight in.

BUY

Healthcare thrives when economies slow.

BUY

Allan Tong’s Discover Picks XLV ETF’s top holdings are Johnson & Johnson, UnitedHealth Group, Pfizer, Abbott Labs, AbbVie, Thermo Fisher, Merck, Eli Lilly and Danaher. A bullish case can be made for almost all all these names. Another plus: the MER is only 0.1%, though the dividend pays a lowly 1.4%. XLV’s PE is merely 6.62%, volumes average a healthy 14.8 billion a day, and its beta is a very stable 0.73. While you can make better gains holding some of the stocks this ETF holds, XLV is a safe way to play the American healthcare stocks in 2022. Read 3 Promising Healthcare Stocks for our full analysis.

BUY

He likes healthcare, given the return to preventative care and elective surgeries. Also, there's a strong pharma pipeline. Stay long in health.

BUY

Allan Tong’s Discover Picks However, if you want to own several in one place or can’t afford to buy one of these stocks individually, XLV is the place to go. It trades on the Nasdaq. It charges an ultra-low MER of 0.12%, trades at merely 4.18x PE and pays a 1.4% dividend. Also, average volumes are a robust 13.9 million and the Beta is a low 0.71. YTD, XLV has lost 7.55%, but Omicron was the major disruptor and restrictions are quickly lifting now. Essentially, you’re buying this ETF for the future. Read 3 Best Cyclical and Value ETFs for our full analysis.

BUY

Healthcare stock with a 5-year horizon? She prefers owning individual names, but XLV includes Thermo-Fisher, BMO, Abbott, etc. Healthcare will change a lot in coming years, and XLV gives you a good representation.

BUY

XLV vs. IBB Has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.

Showing 16 to 30 of 67 entries

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brian Madden

First Avenue Investment Counsel

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Health Care Select Sector SPDR Fund (XLV)